1. Academic Validation
  2. Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer

Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer

  • Sci Rep. 2025 May 15;15(1):16869. doi: 10.1038/s41598-025-01868-5.
Huan Cheng 1 2 Yajiao Shao 1 2 Ao Zhang 1 Caixia Li 1 Xinxin Li 1 Yuxin Fu 1 Jian Ming 3
Affiliations

Affiliations

  • 1 Department of Pathology, General Hospital of Northern Theater Command, No.83, Wenhua Road, Shenhe District, Shenyang, 110016, Liaoning, China.
  • 2 Post-graduate College, China Medical University, No.77, Puhe Road, Shenbei District, Shenyang, 110122, Liaoning, China.
  • 3 Department of Pathology, General Hospital of Northern Theater Command, No.83, Wenhua Road, Shenhe District, Shenyang, 110016, Liaoning, China. mjjgc7878@163.com.
Abstract

Lung Cancer is one of the most commonly diagnosed cancers worldwide and the leading cause of cancer-related deaths worldwide. In recent years, an increasing number of studies have shown that the tumor immune microenvironment (TIME) has a significant impact on the development of lung Cancer. Interleukin-7 (IL-7) is an essential cytokine for the adaptive immune system and plays an important immunoregulatory role in different types of tumors. However, the relationship between IL-7 and TIME in non-small cell lung Cancer (NSCLC) is not yet known. This study found that the expression of MCP-1 and CD11b was correlated with the expression of IL-7/IL-7R. MCP-1, IL-7R, tumor differentiation and tumor stage were the strongest predictors of survival. In addition, IL-7 upregulates MCP-1 through JAK1/STAT3 pathway to affect the migration of MDSCs and exert tumor immunosuppressive effect. Furthermore, CCR2 Inhibitor and depletion of MDSCs suppressed the promoting effect of IL-7 mediated development of lung Cancer. These findings provided the important mechanism that IL-7 upregulate MCP-1 through JAK1/STAT3 pathway to recruit MDSCs and put forth blockage of CCR2 Inhibitor and MDSCs recruitment as a prospective immunotherapy strategy for the treatment of NSCLC.

Keywords

IL-7; MCP-1; MDSCs; NSCLC.

Figures
Products